Home » Stocks » MNPR

Monopar Therapeutics, Inc. (MNPR)

Stock Price: $5.28 USD 0.09 (1.73%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 66.37M
Revenue (ttm) n/a
Net Income (ttm) -6.30M
Shares Out 10.96M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $5.28
Previous Close $5.19
Change ($) 0.09
Change (%) 1.73%
Day's Open 5.13
Day's Range 5.13 - 5.41
Day's Volume 7,572
52-Week Range 4.28 - 17.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes announced a corporate update describing progress in its key programs during the past year and upcoming milestones.

3 weeks ago - Business Wire

Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could poten...

1 month ago - Benzinga

WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed ...

1 month ago - GlobeNewsWire

Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer

1 month ago - GlobeNewsWire

- Initial focus on use in bladder cancer surgery - Initial focus on use in bladder cancer surgery

2 months ago - GlobeNewsWire

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

2 months ago - GlobeNewsWire

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

2 months ago - GlobeNewsWire

WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

2 months ago - GlobeNewsWire

WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

3 months ago - GlobeNewsWire

Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher Thursday after Roth Capital initiated coverage on the stock with a Buy rating and a price target of $49 per share. Monopar Therapeutics is a...

3 months ago - Benzinga

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

-Issued patent expands and strengthens Monopar's existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 

4 months ago - GlobeNewsWire

WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen...

4 months ago - GlobeNewsWire

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

5 months ago - GlobeNewsWire

Validive ® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021

5 months ago - GlobeNewsWire

Strengthens Monopar's Validive IP Portfolio To 2035 Strengthens Monopar's Validive IP Portfolio To 2035

6 months ago - GlobeNewsWire

WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at t...

7 months ago - GlobeNewsWire

WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokin...

8 months ago - GlobeNewsWire

WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI)...

8 months ago - GlobeNewsWire

Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.

Other stocks mentioned: CARS, F, INVE, KGC, LIVX, LLNW, TEVA
8 months ago - InvestorPlace

With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.

Other stocks mentioned: ACI, HD, LULU, MMM, SQM, SWBI, TDOC ...
8 months ago - InvestorPlace

Potential Companion Diagnostic to Monopar’s uPRIT Program Potential Companion Diagnostic to Monopar’s uPRIT Program

8 months ago - GlobeNewsWire

WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), wh...

8 months ago - GlobeNewsWire

Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology

9 months ago - GlobeNewsWire

CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a provisio...

10 months ago - GlobeNewsWire

Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher on Tuesday, after the company announced it joined forces with NorthStar to develop a radio-immuno-therapeutics to target severe coronavirus.

10 months ago - Benzinga

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, wh... [Read more...]

Industry
Biotechnology
IPO Date
Dec 19, 2019
Stock Exchange
NASDAQ
Ticker Symbol
MNPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is 35.00, which is an increase of 562.88% from the latest price.

Price Target
$35.00
(562.88% upside)
Analyst Consensus: Buy